Trifluridine + Tipiracil

DRUG3 trials

Sponsors

Inhibrx Biosciences, Inc, Astellas Pharma Global Development, Inc., M.D. Anderson Cancer Center

Conditions

Advanced Solid TumorsBevacizumabColorectal AdenocarcinomaEwing SarcomaMicrosatellite-stable Colorectal CancerNivolumabStandard of Care

Phase 1

Phase 1 Study of INBRX-109 in Subjects With Locally Advanced or Metastatic Solid Tumors Including Sarcomas

RecruitingNCT03715933

Inhibrx Biosciences, IncColorectal Adenocarcinoma, Ewing Sarcoma

Start: 2018-10-08End: 2029-06-01Target: 411Updated: 2026-09-08

A Study of ASP1570 Taken by Itself, or ASP1570 Taken Together With Either Pembrolizumab, Standard Therapies, or Both, in Adults With Solid Tumors

TerminatedNCT05083481

Astellas Pharma Global Development, Inc.Advanced Solid Tumors

Start: 2021-10-19End: 2026-05-11Updated: 2026-08-14

Phase 2

Phase 2, Single-arm Trial of BMS-986340 in Association With Nivolumab, Trifluridine/Tipiracil and Bevacizumab for Patients Refractory to Standard of Care Treatment and With Microsatellite-stable Colorectal Cancer

SuspendedNCT07011550

M.D. Anderson Cancer CenterBevacizumab, Microsatellite-stable Colorectal Cancer, Nivolumab +1

Start: 2025-08-15End: 2030-07-01Updated: 2026-08-25

Related Papers

Phase 1 study of the tetravalent death receptor 5 agonist ozekibart (INBRX-109) combined with chemotherapy in locally advanced or metastatic, unresectable colorectal adenocarcinoma (CRC).

Journal of Clinical Oncology2026-05-27

Enhanced Antitumor Immunity by ASP1570, a Novel Diacylglycerol Kinase ζ Inhibitor, Offers a Potential Novel Immunotherapy for Treating Cancer

Molecular Cancer Therapeutics2025-03-266 citations

Tetravalent death receptor 5 (DR5) agonist ozekibart (INBRX-109) + FOLFIRI in 2L+ colorectal adenocarcinoma (CRC): Preliminary results from a phase 1 study.

Journal of Clinical Oncology2025-01-271 citations

Abstract A004: Enhanced antitumor immunity by ASP1570 in mouse models: A novel DGKζ inhibitor offers a potential immunotherapy for treating cancer

Molecular Cancer Therapeutics2023-12-01

Preclinical Characterization and Phase I Trial Results of INBRX-109, A Third-Generation, Recombinant, Humanized, Death Receptor 5 Agonist Antibody, in Chondrosarcoma

Clinical Cancer Research2023-06-0240 citations

754 A phase 1/2 study of ASP1570 in participants with locally advanced or metastatic solid tumors who have progressed on, or are ineligible for, all available standard therapies

Regular and Young Investigator Award Abstracts2022-11-011 citations